Trial Profile

GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KUR 501 (Primary) ; Cyclophosphamide; Fludarabine
Indications Neuroblastoma
Focus Adverse reactions; First in man; Proof of concept
Acronyms GINAKIT2

Most Recent Events

19 Sep 2025 Planned number of patients changed from 54 to 70.
19 Sep 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Dec 2027.
13 Nov 2024 Arms increased from 1 to 2. New arm ' Experimental: GINAKIT cells + Etanercept' added newly.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com